脂肪肉瘤潜在作用靶点的研究进展

doi:10.11904/j.issn.1002-3070.2019.01.015

摘要/Abstract

摘要： 脂肪肉瘤(Liposarcoma,LPS)是软组织肉瘤(Soft-tissue sarcoma,STS)中最常见的一种。目前的治疗方法仍然以手术完整切除为主,放、化疗作为辅助治疗手段,但远处转移、不可切除性脂肪肉瘤主要治疗方法疗效有限,未获得广泛认可。随着LPS分子靶向治疗的广泛深入研究,该方面的研究成果显著。新出现的LPS作用靶点包括受体类如酪氨酸激酶受体AXL、成纤维生长因子受体(Fibroblast growth factor receptor,FGFR)、胰岛素样生长因子1受体(Insulin-like growth factor-1 receptor,IGF-1R)、核输出受体XPO1(Exportin-1)、蛋白/酶类如热休克蛋白90(Heat shock protein 90,Hsp90)、双特异性酪氨酸(Y)磷酸化调节激酶1B(Dual-specificity tyrosine(Y)phosphorylation-regulated kinase1B,DYRK1B),信号通路类如SRC/FAK/RHO/ROCK等,它们的抑制在临床前研究中都展现出了良好的抗LPS前景,现将该方面的研究进展情况综述如下。

关键词: 脂肪肉瘤, 作用靶点, 治疗

Abstract: Liposarcoma(LPS)is the most common type of soft-tissue sarcoma(STS).The current treatment methods are still based on complete surgical resection.Radiotherapy and chemotherapy as adjuvant treatment or distant metastasis,and the main treatment of unresectable liposarcoma have limited efficacy,have not widely recognized.With the extensive and in-depth of LPS molecular targeted therapy,the research achievements in this area are remarkable.Emerging targets for LPS include receptors such as tyrosine kinase receptor AXL,fibroblast growth factor receptor(FGFR),insulin-like growth factor-1 receptor(IGF-1R),nuclear export receptor XPO1(Exportin-1),and proteins/enzymes such as heat shock protein 90(Hsp90),bispecific tyrosine(Y)phosphorylation-regulated kinase 1B(DYRK1B)and signal pathways such as SRC/FAK/RHO/ROCK have shown good prospects for anti-LPS in preclinical studies.The research progress in the aspects is summarized as follows.

Key words: Liposarcoma, Targets, Treatment

中图分类号:

R453.9

邢志超综述, 麦威审校. 脂肪肉瘤潜在作用靶点的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 82-86.

XING Zhichao, MAI Wei. Research progress on potential targets of liposarcoma[J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 82-86.

参考文献

1 Jo VY,Fletcher CD.WHO classification of soft tissue tumours:an update based on the 2013(4th)edition[J].Pathology,2014,46(2):95-104.
2 Dodd LG.Update on liposarcoma:a review for cytopathologists[J].Diagn Cytopathol,2012,40(12):1122-1131.
3 Rankin EB,Giaccia AJ.The receptor tyrosine kinase AXL in cancer progression[J].Cancers(Basel),2016,8(11):103.
4 Shen YY,Chen XG,He J,et al.Axl inhibitors as novel cancer therapeutic agents[J].Life Sci,2018,198:99-111.
5 Asiedu MK,Beauchamp-Perez FD,Ingle JN,et al.AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells[J].Oncogene,2014,33(10):1316-1324.
6 May CD,Garnett J,Ma X,et al.AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas[J].BMC Cancer,2015,15:901.
7 Chen Y,Li X,Eswarakumar VP,et al.Fibroblast growth factor(FGF)signaling through PI 3-kinase and Akt/PKB is required for embryoid body differentiation[J].Oncogene,2000,19(33):3750-3756.
8 Hart KC,Robertson SC,Kanemitsu MY,et al.Transformation and Stat activation by derivatives of FGFR1,FGFR3,and FGFR4[J].Oncogene,2000,19(29):3309-3320.
9 LaVallee TM,Prudovsky IA,McMahon GA,et al.Activation of the MAP kinase pathway by FGF-1 correlates with cell proliferation induction while activation of the Src pathway correlates with migration[J].J Cell Biol,1998,141(7):1647-1658.
10 Zhang K,Chu K,Wu X,et al.Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in high-grade liposarcoma[J].Cancer Res,2013,73(4):1298-1307.
11 Künstlinger H,Fassunke J,Schildhaus HU,et al.FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro[J].Oncotarget,2015,6(24):20215-20230.
12 Patil N,Ahmed Kabeer Rasheed S,Abba M,et al.A mechanistic study on the metastasis inducing function of FUS-CHOP fusion protein in liposarcoma[J].Int J Cancer,2014,134(12):2808-2819.
13 Huveneers S,Danen EH.Adhesion signaling-crosstalk between integrins,Src and Rho[J].J Cell Sci,2009,122(8):1059-1069.
14 Danen EH.Src signaling in cancer invasion[J].J Cell Physiol,2010,223(1):14-26.
15 Sievers E,Trautmann M,Kindler D,et al.SRC inhibition represents a potential therapeutic strategy in liposarcoma[J].Int J Cancer,2015,137(11):2578-2588.
16 Tornin J,Hermida-Prado F,Padda RS,et al.FUS-CHOP promotes invasion in myxoid liposarcoma through a SRC/FAK/RHO/ROCK-dependent pathway[J].Neoplasia,2018,20(1):44-56.
17 Iams WT.Molecular pathways:clinical applications and future direction of insulin-like growth factor-1 receptor pathway blockade[J].Clin Cancer Res,2015,21(19):4270-4277.
18 Demicco EG,Torres KE,Ghadimi MP,et al.Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma[J].Mod Pathol,2012,25(2):212-221.
19 Cheng H,Dodge J,Mehl E,et al.Validation of immature adipogenic status and identification of prognostic biomarkers in myxoid liposarcoma using tissue microarrays[J].Hum Pathol,2009,40(9):1244-1251.
20 Trautmann M,Menzel J,Bertling C,et al.FUS-DDIT3 fusion protein-driven IGF-IR signaling is a therapeutic target in myxoid liposarcoma[J].Clin Cancer Res,2017,23(20):6227-6238.
21 Steinmann S,Gali-Muhtasib H,Huebner K,et al.Hsp90 inhibition by AUY922 as an effective treatment strategy against myxoid liposarcoma[J].Cancer Lett,2015,367(2):147-156.
22 Wang T,Goodman MA,McGough RL,et al.Immunohistochemical analysis of expressions of RB1,CDK4,HSP90,cPLA2G4A,and CHMP2B is helpful in distinction between myxofibrosarcoma and myxoid liposarcoma[J].Int J Surg Pathol,2014,22(7):589-599.
23 Steinmann S,Gali-Muhtasib H,Huebner K,et al.Hsp90 inhibition by AUY922 as an effective treatment strategy against myxoid liposarcoma[J].Cancer Lett,2015,367(2):147-156.
24 Safavi S,Järnum S,Vannas C,et al.HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo[J].Oncotarget,2016,7(1):433-445.
25 Gravina GL,Senapedis W,McCauley D,et al.Nucleo-cytoplasmic transport as a therapeutic target of cancer[J].J Hematol Oncol,2014,7:85.
26 Abdul Razak AR,Mau-Soerensen M,Gabrail NY,et al.First-in-class,first-in-human phase I study of selinexor,a selective inhibitor of nuclear export,in patients with advanced solid tumors[J].J Clin Oncol,2016,34(34):4142-4150.
27 Gounder MM,Zer A,Tap WD,et al.Phase IB study of selinexor,a first-in-class inhibitor of nuclear export,in patients with advanced refractory bone or soft tissue sarcoma[J].J Clin Oncol,2016,34(26):3166-3174.
28 Garg M,Kanojia D,Mayakonda A,et al.Molecular mechanism and therapeutic implications of selinexor(KPT-330)in liposarcoma[J].Oncotarget,2017,8(5):7521-7532.
29 Soppa U,Becker W.DYRK protein kinases[J].Curr Biol,2015,25(12):R488-9.
30 Chen H,Shen J,Choy E,et al.Targeting DYRK1B suppresses the proliferation and migration of liposarcoma cells[J].Oncotarget,2018,9(17):13154-13166.

[1]	侯玉雪,李晓莉. Wnt7a与恶性肿瘤的关系及研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 271-275.
[2]	朱琳,张春霞. 纳米载药系统靶向肿瘤干细胞的研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 276-279.
[3]	李珊,赵春波,乔文波. 术中放疗在胰腺癌中的应用进展[J]. 实用肿瘤学杂志, 2019, 33(3): 280-283.
[4]	方琳, 刘超, 张纯慧, 张艳桥. 转移性结直肠癌维持治疗的研究现状与治疗策略[J]. 实用肿瘤学杂志, 2019, 33(2): 173-178.
[5]	丁界先, 张津, 陈永刚, 王兴文综述, 王栓科审校. Wnt信号通路与肿瘤发生的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 73-77.
[6]	张攀, 张迪综述, 戴晓波审校. 复发鼻咽癌再程放射治疗的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 92-96.
[7]	田洋, 吴华星. 超细鼻胃镜在消化道狭窄性疾病中的临床应用[J]. 实用肿瘤学杂志, 2018, 32(6): 550-554.
[8]	李悦, 徐可, 韩增祥, 孙敏, 樊国华综述, 张勇审校. 结肠癌中肿瘤相关巨噬细胞的作用及靶向治疗的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 450-454.
[9]	王元综述, 孙轶华审校. β-连环蛋白在软组织肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 455-459.
[10]	张莉, 方可薇, 岳茜, 王红, 杨汉丰, 徐晓雪. 冷冻消融治疗骨转移瘤的研究进展[J]. 实用肿瘤学杂志, 2018, 32(4): 353-356.
[11]	孙祖刚, 王哲, 陈怀安, 刘硕, 苗文隆. 诱发膀胱癌的常见慢性炎症因素及其免疫治疗的研究进展[J]. 实用肿瘤学杂志, 2018, 32(4): 357-361.
[12]	周洁, 陈钰(综述), 陈道桢(审校). 纳米材料在肿瘤光动力治疗中的应用[J]. 实用肿瘤学杂志, 2018, 32(3): 245-249.
[13]	张婷, 贾迪(综述), 杨丹(审校). 骨肉瘤的生物学治疗进展[J]. 实用肿瘤学杂志, 2018, 32(3): 254-257.
[14]	李林(综述), 李志高(审校). 二甲双胍与不同分子亚型乳腺癌的关系[J]. 实用肿瘤学杂志, 2018, 32(3): 267-270.
[15]	纪巧, 陈丽(综述), 何远桥(审校). 三维组织药敏法在肿瘤个体化精准医疗中的应用[J]. 实用肿瘤学杂志, 2018, 32(3): 280-284.